INTRODUCTION
, mediate neuronal dysfunction in AD (Walsh & Selkoe, 2004) , and are both necessary and sufficient to disrupt learning behavior in a manner that is both rapid, potent and transient (Cleary et al., 2005) . For a detailed discussion on the amyloid hypothesis, the reader is referred to Hardy & Selkoe (2002) Raiha et al., 1996) , depending on, among others, the age of the population under investigation (early-onset vs. late-onset) and the type of study (incidence vs. prevalence).
The search for the actual genes has proven to be difficult. To date, possession of the 134 allele of ApoE is the most robust genetic susceptibility factor for late-onset AD but is neither necessary nor sufficient to cause disease (Tanzi & Bertram, 2005) . Other genes involved are the genes encoding amyloid precursor protein (APP), presenilin-1 (PSEN1), and presenilin-2 (PSEN2).
Specific mutations in these genes cause early-onset familial AD (EOFAD). First discovered in 1991 (Goate et al., 1991) , the number of these fully penetrant mutations has expanded exponentially.
Although such mutations are rare (< 5% of all AD cases), the affected geneswand the biochemical pathways they represent--are excellent starting points for the genetic and functional analysis of AD. Mutations in the gene encoding tau, however, cause a range of different disorders, which are collectively referred to as "tauopathies" (Ingram & Spillantini, 2002 (Pompl et al., 1999) , whereas in yet another lab they perform poorer in a T-maze alternation task and are impaired at acquiring fear to the conditioning context (Corcoran et (Dewachter et al., 2002) , suggesting /-secretase inhibition is a promising target for putative treatment strategies.
-secretase
The third secretase involved in APP processing is the {x-secretase, which metabolizes about 90% of APP. To a certain extent, the {x-secretase can be considered the 'good' secretase as it produces peptides not--or far less than the AI3s-associated with amyloid toxicity (see Fig. 2 ). Thus, although the P3 fragment is also a component of certain amyloid plaques in AD, there have been very few reports of P3 having apoptotic or any other kind of deleterious activity in neurons. As a result, the secretase-processing pathway has been described as the non-amyloidogenic pathway (Naslund et al., 1994; Wei et al., 2002) . A number of enzymes can act as t-secretase in the brain, including the ADAM proteins (ADAM9, ADAM10, and ADAM17). ADAM stands for A Disintegrin and Metallo-proteinase; its members have apparently redundant a-secretase cleavage activities but differential expression patterns (Buxbaum et al., 1998; Karkkainen et al., 2000; Lammich et al., 1999 
